[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# Acasunlimab

Acasunlimab is seeing a significant surge in social media engagement and mentions, with a XXX% increase in engagements and a XX% rise in mentions over the past week. This heightened activity coincides with anticipation for upcoming clinical trial data, particularly for NSCLC, and potential catalysts like PDUFA dates.

### About Acasunlimab
Acasunlimab is a bispecific antibody developed for cancer immunotherapy.  

### Insights
- acasunlimab engagements is up XXXXXX% from the previous week.
- acasunlimab mentions is up XXXXX% from the previous week.

### Engagements: XXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:acasunlimab/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/interactions.tsv)  
Current Value: XXX  
Daily Average: XX  
X Week: XXX +102%  
X Month: XXX +67%  
1-Year High: XXXXX on 2025-10-10  
1-Year Low: X on 2025-09-27  

Engagements by network (24h):
X: XXX

  
  
### Mentions: XX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:acasunlimab/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/posts_active.tsv)  
Current Value: XX  
Daily Average: X  
X Week: XX +22%  
1-Year High: XX on 2025-09-26  
1-Year Low: X on 2025-09-15  

Mentions by network (24h):
X: XX

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:acasunlimab/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning Acasunlimab in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X  
X Week: X -XX%  
1-Year High: X on 2025-09-26  
1-Year Low: X on 2025-09-15  

The most influential creators that mention Acasunlimab in the last XX hours

| Creator                                | Rank | Followers | Posts | Engagements |
| -------                                | ---- | --------- | ----- | ----------- |
| [@Biotwit1](/creator/twitter/Biotwit1) | X    | XXX       | X     | XX          |
| [@grok](/creator/twitter/grok)         | X    | XXXXXXXXX | X     | XX          |

[View More](/list/creators/acasunlimab/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:acasunlimab/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/acasunlimab/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Week: XXX% no change  
X Month: XXX% no change  
1-Year High: XXX% on 2025-09-30  
1-Year Low: XX% on 2025-10-03  

Most Supportive Themes:
- Partnership Success: (60%) The collaboration between BioNTech and Genmab is highlighted as a positive development.
  
Most Critical Themes:
- Clinical Trial Progress: (10%) The success of Acasunlimab depends on the results of ongoing clinical trials.
  

### Top Acasunlimab Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Sounds like you're eyeing $GMAB closely. Recent acquisition of Merus has boosted the stock XX% this month. Darzalex sales look strong per analysts with Q3 earnings due Nov X. PDUFA for Epkinly in 2L+ FL is Nov 30could be a catalyst. Acasunlimab NSCLC trials advancing OS data expected by year-end. Always DYOR 📈"  
[X Link](https://x.com/grok/status/1976639326332330424) [@grok](/creator/x/grok) 2025-10-10T13:21Z 6.8M followers, XXX engagements


"$GMAB Cowen expect Darzalex to meet/beat $3.6B consensus ests vs our $XXX conservatively model Q3 Epkinly net sales of $105M vs cons. $124M. Kesimpta should beat. Tepezza likely to be weak. Rybrevant should continue to grow well. Acasunlimab 2L+ NSCLC update on OS by YE25. Nov XX 2025 PDUFA for 2L+ FL and Ph3 1L/2L DLBCL"  
[X Link](https://x.com/semodough/status/1976637016801481084) [@semodough](/creator/x/semodough) 2025-10-10T13:12Z 41.9K followers, 2895 engagements


"@JacobPlieth @BertrandBio @ByMadeleineA $GMAB GEN1046 Acasunlimab news SOON. Something like this. PD-L14-1BB gives costimulation but INCOMPLETE PD-1 blockade. Adding a PD-1 inhibitor fully releases inhibition. Together they provide activation plus costimulation driving durable immunity. Guess U knew this by now :-)"  
[X Link](https://x.com/Biotwit1/status/1975902927891169666) [@Biotwit1](/creator/x/Biotwit1) 2025-10-08T12:35Z XXX followers, XXX engagements


"@jodmark11 @TheRayMyers @geokoutalidis Merus CRC data in November and likely also Acasunlimab at SITC hs ben mentioned many times by Gmab. Believe there is some 20+ abstracts on Epcoritamab at ASH too. Read the company presentation"  
[X Link](https://x.com/Biotwit1/status/1973028830622429301) [@Biotwit1](/creator/x/Biotwit1) 2025-09-30T14:15Z XXX followers, XXX engagements